Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized quadruple-blind trial of batoclimab in generalized myasthenia gravis
2024-512258-91-00Phase 3Completed
- Sponsor
- Immunovant, Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, triple-blind trial in myasthenia gravis (MG) comparing Batoclimab with Placebo (2 arms). Primary endpoint: Change from Period 1 baseline in MG-ADL score to Week 12 for AChRAb+ participants. Started Jul 2024; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-512258-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512258-91-00.